Loading...
The risky reliance on small surrogate endpoint studies when planning a large prevention trial
The definitive evaluation of treatment to prevent a chronic disease with low incidence in middle age, such as cancer or cardiovascular disease, requires a trial with a large sample size of perhaps 20,000 or more. To help decide whether to implement a large true endpoint trial, investigators first ty...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2012
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3616635/ https://ncbi.nlm.nih.gov/pubmed/23565041 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1467-985X.2012.01052.x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|